Redefying the therapeutic strategies against cardiorenal morbidity and mortality: Patient phenotypes

Table 1 Proposed Measures of prognostic enrichment

Category	Parameters	Evaluation method
		Continuous	Discrete based on trials
Laboratory	eGFR	CKD-EPI (mL/min/1.73 m2)	CKD stages 1,2,3a/b,4,5
	uACR	Mg albumin/g creatinine	Albuminuria stages A1,A2,A3
	hs-CRP
	Serum magnesium
	PTH	Intact PTH (pg/mL)	KDIGO < 150, 150-500, > 500 pg/mL
	Anemia variables	Ht/Hb/TSAT/Ferritin/Hepcidin
Radiology	LVMI	LV mass indexed to body surface area (g/m2)	Geometry types
	Lateral abdominal X-ray	Scale from 0-24	Leena Kaupilla Score ≤ 4 vs > 4
	Aortic stiffness	Pulse wave velocity carotid-femoral PWV (m/s)	CF-PWV < 8.8, 8.8-12, > 12 m/s
Clinical status	Frailty	Nine-point clinical frailty scale
	Aortic stiffness	Pulse pressure (mmHg)
	Physical activity	Handgrip strength
	Diet	Mediterranean Diet Score Panagiotakos Scale 0-24
Co-morbidities	DM, CAD, PAD, stroke, COPD		Charlson comorbidity index
Bones	Mineral bone density (DEXA)	Values from DEXA (g/cm2)	Ostopenia ostoporosis

eGFR: Estimated glomerular filtration rate; uACR: Urinary albumin to creatinine ratio; PTH: Parathyroid hormone; Ht: Haematocrit; Hb: Haemoglobin; TSAT: Transferrin saturation; LVMI: Left ventricular mass index; DM: Diabetes mellitus; CAD: Coronary artery disease; PAD: Peripheral artery disease; COPD: Chronic obstructive pulmonary disease; CKD-EPI: Chronic kidney disease-epidemiology collaboration formula; KDIGO: Kidney Disease: Improving Global Outcomes; CF-PWV: Carotid to femoral pulse wave velocity; DEXA: Dual energy X-ray absorptiometry.